Biotech

All Articles

Actinogen's cortisol blocker neglects period 2 anxiety study

.Actinogen Medical's cortisol blocker has actually missed out on the main endpoint of a stage 2 rese...

Bivictrix decides going exclusive only means to take ADC right into facility

.Antibody-drug conjugates (ADCs) have been at the center of lots of a billion-dollar biobuck licensi...

TPG leadings up funds to $580M for expenditures all over lifestyle sciences

.Resource manager TPG, which has assisted biotechs like Sionna Rehabs and also Santa Clam Ana Biogra...

Merck stops period 3 TIGIT test in lung cancer for futility

.Merck &amp Co.'s TIGIT system has actually experienced yet another setback. Months after shuttering...

After a difficult year, Exscientia folds up in to Recursion

.After a year specified through pipeline hairstyles, the shift of its own CEO and also layoffs, Exsc...

Cullinan, after $25M offer, return bispecific to Harbour

.Cullinan Therapy was blown away sufficient along with Port BioMed's bispecific immune reactor that ...

A better check out Intense Biotech's Fierce 15

.In this particular full week's incident of "The Leading Pipe," our experts're diving in to Intense ...

Lilly deals with phase 2 breakdown of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's celebration celebrating the approval ...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of considerable management hirings, shooting...

Lykos will definitely ask FDA to reevaluate its own selection adhering to being rejected of MDMA therapy for post-traumatic stress disorder

.Complying with an inadequate showing for Lykos Rehabs' MDMA applicant for trauma at a latest FDA ad...